Zoetis Inc. (NYSE:ZTS) Shares Sold by Campbell Newman Asset Management Inc.

Campbell Newman Asset Management Inc. lowered its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 11.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 97,194 shares of the company's stock after selling 12,163 shares during the period. Zoetis makes up approximately 1.3% of Campbell Newman Asset Management Inc.'s investment portfolio, making the stock its 29th largest holding. Campbell Newman Asset Management Inc.'s holdings in Zoetis were worth $15,836,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ZTS. Cherry Creek Investment Advisors Inc. increased its stake in shares of Zoetis by 2.0% in the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company's stock worth $590,000 after acquiring an additional 58 shares during the period. Grove Bank & Trust boosted its holdings in Zoetis by 0.5% in the third quarter. Grove Bank & Trust now owns 11,763 shares of the company's stock valued at $2,298,000 after purchasing an additional 61 shares during the last quarter. Hancock Whitney Corp boosted its holdings in Zoetis by 0.3% in the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company's stock valued at $3,628,000 after purchasing an additional 61 shares during the last quarter. Strategy Asset Managers LLC grew its position in Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company's stock worth $356,000 after purchasing an additional 62 shares during the period. Finally, Edge Capital Group LLC raised its stake in shares of Zoetis by 3.7% during the 2nd quarter. Edge Capital Group LLC now owns 1,786 shares of the company's stock valued at $310,000 after buying an additional 64 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of several analyst reports. JPMorgan Chase & Co. raised their target price on Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a "neutral" rating and a $196.00 target price for the company. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an "outperform" rating and a $215.00 price target on the stock. Finally, Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $211.89.

Zoetis Price Performance

Shares of ZTS stock traded up $2.82 on Wednesday, reaching $167.23. 2,988,342 shares of the company were exchanged, compared to its average volume of 2,649,364. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The business has a 50-day moving average price of $171.31 and a 200 day moving average price of $180.16. The company has a market cap of $75.45 billion, a price-to-earnings ratio of 31.43, a P/E/G ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.29 billion. During the same period in the previous year, the firm posted $1.36 EPS. Zoetis's revenue was up 11.6% compared to the same quarter last year. Equities research analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. This is a positive change from Zoetis's previous quarterly dividend of $0.43. Zoetis's dividend payout ratio (DPR) is presently 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.